Bullous Pemphigoid: Trigger and Predisposing Factors
Abstract
:1. Introduction
2. Trigger Factors
2.1. Drugs
2.1.1. Dipeptidyl Peptidase 4 Inhibitors (DPP-4i)
2.1.2. TNF-α Inhibitors
2.1.3. Antibiotics
2.1.4. Diuretics
2.1.5. PD-1 and PD-L1 Immune-Checkpoint Blockade
2.1.6. Neuroleptics
2.1.7. Contact Pemphigoid
2.2. Vaccines
2.3. Infections
2.4. Physical Factors
2.5. Transplantation
2.6. Nutrition
3. Predisposing Factors
3.1. Genetic Susceptibility
3.2. Comorbidities
3.2.1. Neurologic Diseases
3.2.2. Other Autoimmune and Dermatologic Diseases
3.2.3. Neoplasms
3.2.4. Cardiovascular Diseases
3.3. Aging
4. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Kasperkiewicz, M.; Zillikens, D. The Pathophysiology of Bullous Pemphigoid. Clin. Rev. Allergy Immunol. 2007, 33, 67–77. [Google Scholar] [CrossRef] [PubMed]
- Feliciani, C.; Caldarola, G.; Kneisel, A.; Podstawa, E.; Pfütze, M.; Pfützner, W.; Hertl, M. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses. Br. J. Dermatol. 2009, 161, 306–312. [Google Scholar] [CrossRef] [PubMed]
- Fania, L.; Caldarola, G.; Müller, R.; Brandt, O.; Pellicano, R.; Feliciani, C.; Hertl, M. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses. Clin. Immunol. 2012, 143, 236–245. [Google Scholar] [CrossRef]
- Di Zenzo, G.; Thoma-Uszynski, S.; Fontao, L.; Calabresi, V.; Hofmann, S.; Hellmark, T.; Sebbag, N.; Pedicelli, C.; Sera, F.; Lacour, J.; et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin. Immunol. 2008, 128, 415–426. [Google Scholar] [CrossRef]
- Thoma-Uszynski, S.; Uter, W.; Schwietzke, S.; Schuler, G.; Borradori, L.; Hertl, M. Autoreactive T and B Cells from Bullous Pemphigoid (BP) Patients Recognize Epitopes Clustered in Distinct Regions of BP180 and BP230. J. Immunol. 2006, 176, 2015–2023. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arakawa, M.; Ishii, N.; Karashima, T.; Nakama, T.; Yasumoto, S.; Tsuruta, D.; Dainichi, T.; Hamada, T.; Hashimoto, T. Lesional Th17 cells and regulatory T-cells in bullous pemphigoid. Exp. Dermatol. 2011, 20, 1022–1024. [Google Scholar] [CrossRef] [PubMed]
- Goldring, C.E.; Sanderson, J.P.; Naisbitt, D.J. Drugs as Haptens, Antigens, and Immunogens. In Drug Hypersensitivity; Karger Publishers: Basel, Switzerland, 2007. [Google Scholar]
- Nelson, C.A.; Singer, S.; Chen, T.; Puleo, A.E.; Lian, C.G.; Wei, E.X.; Giobbie-Hurder, A.; Mostaghimi, A.; Leboeuf, N.R. Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes. J. Am. Acad. Dermatol. 2020. [Google Scholar] [CrossRef]
- Popadic, S.; Skiljevic, D.; Medenica, L. Bullous pemphigoid induced by penicillamine in a patient with Wilson disease. Am. J. Clin. Dermatol. 2009, 10, 36–38. [Google Scholar] [CrossRef]
- Cozzani, E.; Chinazzo, C.; Burlando, M.; Romagnoli, M.; Parodi, A. Ciprofloxacin as a Trigger for Bullous Pemphigoid. Am. J. Ther. 2016, 23, e1202–e1204. [Google Scholar] [CrossRef] [PubMed]
- Harada, M.; Yoneda, A.; Haruyama, S.; Yabuki, K.; Honma, Y.; Hiura, M.; Shibata, M.; Matsuoka, H.; Uchiwa, Y. Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma. Intern. Med. 2017. [Google Scholar] [CrossRef] [Green Version]
- Pankakoski, A.; Sintonen, H.; Ranki, A.; Kluger, N. Comorbidities of bullous pemphigoid in a Finnish cohort. Eur. J. Dermatol. 2018, 28, 157–161. [Google Scholar] [CrossRef] [PubMed]
- Ma, H.-J.; Hu, R.; Jia, C.-Y.; Yang, Y.; Song, L.-J. Case of drug-induced bullous pemphigoid by levofloxacin. J. Dermatol. 2012, 39, 1086–1087. [Google Scholar] [CrossRef] [PubMed]
- Carlos, G.; Anforth, R.; Chou, S.; Clements, A.; Fernandez-Penas, P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015, 25, 265–268. [Google Scholar] [CrossRef] [PubMed]
- Naidoo, J.; Schindler, K.; Querfeld, C.; Busam, K.J.; Cunningham, J.; Page, D.B.; Postow, M.A.; Weinstein, A.; Lucas, A.S.; Ciccolini, K.T.; et al. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol. Res. 2016, 4, 383–389. [Google Scholar] [CrossRef] [Green Version]
- Parakh, S.; Nguyen, R.; Opie, J.M.; Andrews, M.C. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. Australas. J. Dermatol. 2016, 58, e109–e112. [Google Scholar] [CrossRef]
- Rofe, O.; Bar-Sela, G.; Keidar, Z.; Sezin, T.; Sadik, C.D.; Bergman, R. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clin. Exp. Dermatol. 2017, 42, 309–312. [Google Scholar] [CrossRef]
- Siegel, J.; Totonchy, M.; Damsky, W.; Berk-Krauss, J.; Castiglione, F.; Sznol, M.; Petrylak, D.P.; Fischbach, N.; Goldberg, S.B.; Decker, R.H.; et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J. Am. Acad. Dermatol. 2018, 79, 1081–1088. [Google Scholar] [CrossRef]
- Sadik, C.D.; Langan, E.A.; Grätz, V.; Zillikens, D.; Terheyden, P. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid. Front. Immunol. 2019, 10, 1934. [Google Scholar] [CrossRef] [Green Version]
- Vassileva, S. Drug-induced pemphigoid: Bullous and cicatricial. Clin. Dermatol. 1998, 16, 379–387. [Google Scholar] [CrossRef]
- Warner, C.; Kwak, Y.; Glover, M.H.; Davis, L.S. Bullous pemphigoid induced by hydrochlorothiazide therapy. J. Drugs Dermatol. 2014, 13, 360–362. [Google Scholar]
- Moitra, S.; Sen, S.; Banerjee, I.; Sikder, A.; Das, P. Metronidazole-Induced Bullous Pemphigoid: A Case Report. J. Clin. Diagn. Res. 2015, 9, FD01–FD03. [Google Scholar] [CrossRef] [PubMed]
- Bordignon, M.; Fortina, A.B.; Pigozzi, B.; Tarantello, M.; Alaibac, M. Bullous Pemphigoid during Long-Term TNF-α Blocker Therapy. Dermatology 2009, 219, 357–358. [Google Scholar] [CrossRef] [PubMed]
- Gaudin, O.; Seta, V.; Alexandre, M.; Bohelay, G.; Aucouturier, F.; Mignot-Grootenboer, S.; Ingen-Housz-Oro, S.; Bernardeschi, C.; Schneider, P.; Mellottee, B.; et al. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients. Front. Immunol. 2018, 9. [Google Scholar] [CrossRef]
- Pasmatzi, E.; Monastirli, A.; Habeos, J.; Georgiou, S.; Tsambaos, D. Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases. Diabetes Care 2011, 34, e133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Skandalis, K.; Spirova, M.; Gaitanis, G.; Tsartsarakis, A.; Bassukas, I. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J. Eur. Acad. Dermatol. Venereol. 2011, 26, 249–253. [Google Scholar] [CrossRef]
- Aouidad, I.; Fite, C.; Marinho, E.; Deschamps, L.; Crickx, B.; Descamps, V. A Case Report of Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors. JAMA Dermatol. 2013, 149, 243–245. [Google Scholar] [CrossRef]
- Mendonça, F.; Martín-Gutierrez, F.J.; Rios-Martin, J.J.; Camacho-Martinez, F. Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors—One due to Linagliptin. Dermatology 2016, 232, 249–253. [Google Scholar] [CrossRef]
- Béné, J.; Jacobsoone, A.; Coupé, P.; Auffret, M.; Babai, S.; Hillaire-Buys, D.; Jean-Pastor, M.-J.; Vonarx, M.; Vermersch, A.; Tronquoy, A.-F.; et al. Bullous pemphigoid induced by vildagliptin: A report of three cases. Fundam. Clin. Pharmacol. 2014, 29, 112–114. [Google Scholar] [CrossRef]
- García-Díez, I.; Ivars, M.; Aventín, D.L.; Ishii, N.; Hashimoto, T.; Iranzo, P.; Pujol, R.M.; Espana, A.; Herrero-González, J.E. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization. Int. J. Dermatol. 2018, 57, 810–816. [Google Scholar] [CrossRef] [Green Version]
- Mai, Y.; Nishie, W.; Sato, K.; Hotta, M.; Izumi, K.; Ito, K.; Hosokawa, K.; Shimizu, H. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature. Front. Immunol. 2018, 9. [Google Scholar] [CrossRef] [Green Version]
- Fania, L.; Salemme, A.; Provini, A.; Pagnanelli, G.; Collina, M.C.; Abeni, D.; Didona, B.; Di Zenzo, G.; Mazzanti, C. Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. J. Am. Acad. Dermatol. 2018, 78, 592–595. [Google Scholar] [CrossRef] [PubMed]
- Ibn Sellam, A.; Soualhi, M.; Zahraoui, R.; Marc, K.; Benamor, J.; Bourkadi, J.; Iraqi, G. Une forme rare de toxidermie induite par la rifampicine: La pemphigoïde bulleuse. Rev. Mal. Respir. 2011, 28, 365–371. [Google Scholar] [CrossRef] [PubMed]
- Takama, H.; Yoshida, M.; Izumi, K.; Yanagishita, T.; Muto, J.; Ohshima, Y.; Nishie, W.; Shimizu, H.; Akiyama, M.; Watanabe, D. Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading. Acta Derm. Venereol. 2018, 98, 983–984. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lindgren, O.; Varpuluoma, O.; Tuusa, J.; Ilonen, J.; Huilaja, L.; Kokkonen, N.; Tasanen, K. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid. Acta Derm. Venereol. 2019, 99, 602–609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mai, Y.; Nishie, W.; Izumi, K.; Shimizu, H. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180. Front. Immunol. 2019, 10. [Google Scholar] [CrossRef] [PubMed]
- Hayashi, M.; Tsunoda, T.; Sato, F.; Yaguchi, Y.; Igarashi, M.; Izumi, K.; Nishie, W.; Ishii, N.; Okamura, K.; Suzuki, T.; et al. Clinical and immunological characterization of 14 cases of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A single-centre study. Br. J. Dermatol. 2019, 182, 806–807. [Google Scholar] [CrossRef] [PubMed]
- Jha, A.; Misra, A.; Gupta, R.; Ghosh, A.; Tyagi, K.; Dutta, K.; Arora, B.; Durani, S. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 213–216. [Google Scholar] [CrossRef]
- Monnier-Murina, K.; Du Thanh, A.; Merlet-Albran, S.; Guillot, B.; Dereure, O. Bullous Pemphigoid Occurring during Efalizumab Treatment for Psoriasis: A Paradoxical Auto-Immune Reaction? Dermatology 2009, 219, 89–90. [Google Scholar] [CrossRef]
- Stausbøl-Grøn, B.; Deleuran, M.; Hansen, E.S.; Kragballe, K. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin. Exp. Dermatol. 2009, 34, e285–e286. [Google Scholar] [CrossRef]
- Wessman, L.L.; Blixt, E.K.; Wetter, D.A.; Miest, R.Y. Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis. JAAD Case Rep. 2017, 3, 339–341. [Google Scholar] [CrossRef]
- Hoffmann, S.; Berneburg, M.; Schreml, S. Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis. Case Rep. Dermatol. 2018, 10, 145–148. [Google Scholar] [CrossRef] [PubMed]
- Ricci, M.; Zauli, S.; Zelante, A.; Trevisani, L.; Virgili, A.; Bettoli, V. Bullous pemphigoid occurring under anti-tumor necrosis factor-α therapy. Int. J. Color. Dis. 2014, 29, 1573–1574. [Google Scholar] [CrossRef] [PubMed]
- Boussemart, L.; Jacobelli, S.; Batteux, F.; Goulvestre, C.; Grange, P.; Carlotti, A.; Morini, J.; Gorin, I.; Ziza, J.; Avril, M.; et al. Autoimmune Bullous Skin Diseases Occurring under Anti-Tumor Necrosis Factor Therapy: Two Case Reports. Dermatology 2010, 221, 201–205. [Google Scholar] [CrossRef] [PubMed]
- Wilmer, E.N.; Becker, N.; Chen, A.; Kroumpouzos, G. Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient. JAAD Case Rep. 2016, 2, 25–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kridin, K.; Amber, K.; Khamaisi, M.; Comaneshter, R.; Batat, E.; Cohen, A.D. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study. Immunol. Res. 2018, 66, 425–430. [Google Scholar] [CrossRef]
- Izumi, K.; Nishie, W.; Mai, Y.; Wada, M.; Natsuga, K.; Ujiie, H.; Iwata, H.; Yamagami, J.; Shimizu, H. Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid. J. Investig. Dermatol. 2016, 136, 2201–2210. [Google Scholar] [CrossRef] [Green Version]
- Forssmann, U.; Stoetzer, C.; Stephan, M.; Kruschinski, C.; Skripuletz, T.; Schade, J.; Schmiedl, A.; Pabst, R.; Wagner, L.; Hoffmann, T.; et al. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J. Immunol. 2008, 181, 1120–1127. [Google Scholar] [CrossRef] [Green Version]
- Yoshiji, S.; Murakami, T.; Harashima, S.; Ko, R.; Kashima, R.; Yabe, D.; Ogura, M.; Doi, K.; Inagaki, N. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases. J. Diabetes Investig. 2017, 9, 445–447. [Google Scholar] [CrossRef]
- Haber, R.; Fayad, A.M.; Stephan, F.; Obeid, G.; Tomb, R. Bullous Pemphigoid Associated With Linagliptin Treatment. JAMA Dermatol. 2016, 152, 224. [Google Scholar] [CrossRef] [Green Version]
- Sakai, A.; Shimomura, Y.; Ansai, O.; Saito, Y.; Tomii, K.; Tsuchida, Y.; Iwata, H.; Ujiie, H.; Shimizu, H.; Abe, R. Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP 180. Br. J. Dermatol. 2016, 176, 541–543. [Google Scholar] [CrossRef]
- Mai, Y.; Nishie, W.; Izumi, K.; Yoshimoto, N.; Morita, Y.; Watanabe, M.; Toyonaga, E.; Ujiie, H.; Iwata, H.; Fujita, Y.; et al. Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: A report of three patients. Br. J. Dermatol. 2018, 179, 790–791. [Google Scholar] [CrossRef] [PubMed]
- Oya, K.; Fujii, M.; Taguchi, S.; Nishie, W.; Izumi, K.; Shimizu, H. Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment. Eur. J. Dermatol. 2018, 28, 250–251. [Google Scholar] [CrossRef] [PubMed]
- Guliani, A.; Bishnoi, A.; Aggarwal, D.; Parsad, D. Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes. Postgrad. Med. J. 2018, 94, 662–663. [Google Scholar] [CrossRef]
- Maki, N.; Nishie, W.; Takazawa, M.; Kakurai, M.; Yamada, T.; Umemoto, N.; Kawase, M.; Izumi, K.; Shimizu, H.; Demitsu, T. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis. J. Dermatol. 2018, 45, 600–602. [Google Scholar] [CrossRef] [PubMed]
- Benzaquen, M.; Borradori, L.; Berbis, P.; Cazzaniga, S.; Valéro, R.; Richard, M.-A.; Feldmeyer, L. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. J. Am. Acad. Dermatol. 2018, 78, 1090–1096. [Google Scholar] [CrossRef] [Green Version]
- Varpuluoma, O.; Försti, A.-K.; Jokelainen, J.; Turpeinen, M.; Timonen, M.; Huilaja, L.; Tasanen, K. Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study. J. Investig. Dermatol. 2018, 138, 1659–1661. [Google Scholar] [CrossRef] [Green Version]
- Kawaguchi, Y.; Shimauchi, R.; Nishibori, N.; Kawashima, K.; Oshitani, S.; Fujiya, A.; Shibata, T.; Ohashi, N.; Izumi, K.; Nishie, W.; et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. J. Diabetes Investig. 2018, 10, 392–398. [Google Scholar] [CrossRef]
- Kridin, K.; Bergman, R. Association of Bullous Pemphigoid with Dipeptidyl-Peptidase 4 Inhibitors in Patients with Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. JAMA Dermatol. 2018, 154, 1152–1158. [Google Scholar] [CrossRef]
- Plaquevent, M.; Tétart, F.; Fardet, L.; Ingen-Housz-Oro, S.; Valeyrie-Allanore, L.; Bernard, P.; Hebert, V.; Roussel, A.; Avenel-Audran, M.; Chaby, G.; et al. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. J. Investig. Dermatol. 2019, 139, 835–841. [Google Scholar] [CrossRef] [Green Version]
- Lee, S.G.; Lee, H.J.; Yoon, M.S.; Kim, N.H. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes. JAMA Dermatol. 2019, 155, 172–177. [Google Scholar] [CrossRef]
- Douros, A.; Rouette, J.; Yin, H.; Yu, O.H.Y.; Filion, K.B.; Azoulay, L. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes. Diabetes Care 2019, 42, 1496–1503. [Google Scholar] [CrossRef] [PubMed]
- Carnovale, C.; Mazhar, F.; Arzenton, E.; Moretti, U.; Pozzi, M.; Mosini, G.; Leoni, O.; Scatigna, M.; Clementi, E.; Radice, S. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: A pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®. Expert Opin. Drug Saf. 2019, 18, 1099–1108. [Google Scholar] [CrossRef] [PubMed]
- Magdaleno-Tapial, J.; Valenzuela-Oñate, C.; Hurtado, Á.E.; Ortiz-Salvador, J.M.; Subiabre-Ferrer, D.; Ferrer-Guillén, B.; Giacaman-von der Weth, M.; Martínez, M.G.L.; Martínez-Domenech, Á.; Hernández-Bel, P.; et al. Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study. Actas Dermosifiliogr. 2019. [Google Scholar] [CrossRef]
- Kodera, R.; Chiba, Y.; Tamura, Y.; Miyazawa, R.; Tanei, R.; Mori, S.; Ito, H.; Araki, A. Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors. Jpn. J. Geriatr. 2019, 56, 43–50. [Google Scholar] [CrossRef] [PubMed]
- Guo, J.-Y.; Chen, H.-H.; Yang, Y.-C.; Wu, P.-Y.; Chang, M.-P.; Chen, C.-C. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study. J. Diabetes Complicat. 2020, 34, 107515. [Google Scholar] [CrossRef] [PubMed]
- Reolid, A.; Muñoz-Aceituno, E.; Rodríguez-Jiménez, P.; González-Rojano, E.; Llamas-Velasco, M.; Fraga, J.; Daudén, E. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database. Int. J. Dermatol. 2019, 59, 197–206. [Google Scholar] [CrossRef]
- Hung, C.-T.; Liu, J.-S.; Cheng, C.-Y.; Chiang, C.-P.; Chien, W.-C.; Wang, W.-M. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan. J. Dermatol. 2019, 47, 245–250. [Google Scholar] [CrossRef]
- Fania, L.; Di Zenzo, G.; Didona, B.; Pilla, M.A.; Sobrino, L.; Panebianco, A.; Mazzanti, C.; Abeni, D. Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade. J. Eur. Acad. Dermatol. Venereol. 2018, 32, e153–e154. [Google Scholar] [CrossRef]
- Bene, J.; Moulis, G.; Bennani, I.; Auffret, M.; Coupe, P.; Babai, S.; Hillaire-Buys, D.; Micallef, J.; Gautier, S. The French Association of Regional Pharmacovigilance Centres Bullous pemphigoid and dipeptidyl peptidase IV-inhibitors: A Case/Non-Case study in the French Pharmacovigilance Database. Br. J. Dermatol. 2016, 175, 296–301. [Google Scholar] [CrossRef]
- Garcia, M.; Aranburu, M.A.; Palacios-Zabalza, I.; Lertxundi, U.; Aguirre, C. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: A case report and analysis of cases reported in the European pharmacovigilance database. J. Clin. Pharm. Ther. 2016, 41, 368–370. [Google Scholar] [CrossRef]
- Keseroglu, H.O.; Taş-Aygar, G.; Gönül, M.; Gököz, O.; Ersoy-Evans, S. A Case of Bullous Pemphigoid Induced by Vildagliptin. Cutan. Ocul. Toxicol. 2016, 36, 201–202. [Google Scholar] [CrossRef] [PubMed]
- Schaffer, C.; Buclin, T.; Jornayvaz, F.R.; Cazzaniga, S.; Borradori, L.; Gilliet, M.; Feldmeyer, L. Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid. Dermatology 2017, 233, 401–403. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ujiie, H.; Muramatsu, K.; Mushiroda, T.; Ozeki, T.; Miyoshi, H.; Iwata, H.; Nakamura, A.; Nomoto, H.; Cho, K.Y.; Sato, N.; et al. HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. J. Investig. Dermatol. 2018, 138, 1201–1204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ameglio, F.; D’Auria, L.; Cordiali-Fei, P.; Mussi, A.; Valenzano, L.; D’Agosto, G.; Ferraro, C.; Bonifati, C.; Giacalone, B. Bullous pemphigoid and pemphigus vulgaris: Correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels. J. Biol. Regul. Homeost. Agents 1997, 11, 148–153. [Google Scholar] [PubMed]
- Munera-Campos, M.; Ballesca, F.; Carrascosa, J. Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature. Actas Dermo-Sifiliogr. (Engl. Ed.) 2018, 109, 791–800. [Google Scholar] [CrossRef]
- Stavropoulos, P.; Soura, E.; Antoniou, C. Drug-induced pemphigoid: A review of the literature. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 1133–1140. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.Y.; Bates, M.E.; Jarjour, N.N.; Busse, W.W.; Bertics, P.J.; Kelly, E.A. Generation of Th1 and Th2 Chemokines by Human Eosinophils: Evidence for a Critical Role of TNF-α. J. Immunol. 2007, 179, 4840–4848. [Google Scholar] [CrossRef] [Green Version]
- Kanahara, S.M.; Agrawal, A. Drug-induced bullous pemphigoid. J. Gen. Intern. Med. 2016, 31, 1393–1394. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bernard, P.; Antonicelli, F. Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment. Am. J. Clin. Dermatol. 2017, 18, 513–528. [Google Scholar] [CrossRef]
- Lloyd-Lavery, A.; Chi, C.; Wojnarowska, F.; Taghipour, K. The Associations between Bullous Pemphigoid and Drug Use. JAMA Dermatol. 2013, 149, 58–62. [Google Scholar] [CrossRef] [Green Version]
- Bastuji-Garin, S.; on behalf of the French Study Group for Bullous Diseases; Joly, P.; Lemordant, P.; Sparsa, A.; Bedane, C.; Delaporte, E.; Roujeau, J.-C.; Bernard, P.; Guillaume, J.-C.; et al. Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case–Control Study. J. Investig. Dermatol. 2011, 131, 637–643. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Francisco, L.M.; Sage, P.T.; Sharpe, A. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 2010, 236, 219–242. [Google Scholar] [CrossRef] [PubMed]
- Thibult, M.-L.; Mamessier, E.; Gertner-Dardenne, J.; Pastor, S.; Just-Landi, S.; Xerri, L.; Chetaille, B.; Olive, D. PD-1 is a novel regulator of human B-cell activation. Int. Immunol. 2012, 25, 129–137. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xia, Y.; Medeiros, L.J.; Young, K.H. Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim. Biophys. Acta (BBA) Rev. Cancer 2016, 1865, 58–71. [Google Scholar] [CrossRef] [Green Version]
- Jour, G.; Glitza, I.C.; Ellis, R.M.; Torres-Cabala, C.A.; Tetzlaff, M.; Li, J.Y.; Nagarajan, P.; Huen, A.; Aung, P.P.; Ivan, D.; et al. Autoimmune Dermatologic Toxicities from Immune Checkpoint Blockade with anti-PD-1 Antibody Therapy: A Report on Bullous Skin Eruptions. J. Cutan. Pathol. 2016, 43, 688–696. [Google Scholar] [CrossRef]
- Patsatsi, A.; Vyzantiadis, T.-A.; Chrysomallis, F.; Sotiriadis, D.; Devliotou-Panagiotidou, D. Medication history of a series of patients with bullous pemphigoid from northern Greece—Observations and discussion. Int. J. Dermatol. 2009, 48, 132–135. [Google Scholar] [CrossRef]
- Bastuji-Garin, S.; Joly, P.; Picard-Dahan, C.; Bernard, P.; Vaillant, L.; Pauwels, C.; Salagnac, V.; Lok, C.; Roujeau, J.-C. Drugs Associated With Bullous Pemphigoid. Arch. Dermatol. 1996, 132, 272–276. [Google Scholar] [CrossRef]
- Varpuluoma, O.; Jokelainen, J.; Försti, A.-K.; Turpeinen, M.; Timonen, M.; Huilaja, L.; Tasanen, K. Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: A case–control study. J. Am. Acad. Dermatol. 2019, 81, 250–253. [Google Scholar] [CrossRef] [Green Version]
- Doval, I.G.; Mayo, E.; Fariña, J.N.; Cruces, M. Bullous pemphigoid triggered by influenza vaccination? Ecological study in Galicia, Spain. Br. J. Dermatol. 2006, 155, 820–823. [Google Scholar] [CrossRef]
- Fournier, B.; Descamps, V.; Bouscarat, F.; Crickx, B.; Belaich, S. Bullous pemphigoid induced by vaccination. Br. J. Dermatol. 1996, 135, 153–154. [Google Scholar] [CrossRef]
- Doval, I.G. Generalized Bullous Fixed Drug Eruption after Influenza Vaccination, Simulating Bullous Pemphigoid. Acta Derm. Venereol. 2001, 81, 450–451. [Google Scholar] [CrossRef]
- Downs, A.M.; Lear, J.T.; Bower, C.P.; Kennedy, C.T. Does influenza vaccination induce bullous pemphigoid? A report of four cases. Br. J. Dermatol. 1998, 138, 363. [Google Scholar] [CrossRef] [PubMed]
- Guerra, L.; Pedicelli, C.; Fania, L.; De Luca, N.; Condorelli, A.G.; Mazzanti, C.; Di Zenzo, G. Infantile bullous pemphigoid following vaccination. Eur. J. Dermatol. 2018, 28, 708–710. [Google Scholar] [PubMed]
- Baykal, C.; Okan, G.; Sarica, R. Childhood bullous pemphigoid developed after the first vaccination. J. Am. Acad. Dermatol. 2001, 44, 348–350. [Google Scholar] [CrossRef]
- Schiavo, A.L.; Ruocco, E.; Brancaccio, G.; Caccavale, S.; Ruocco, V.; Wolf, R. Bullous pemphigoid: Etiology, pathogenesis, and inducing factors: Facts and controversies. Clin. Dermatol. 2013, 31, 391–399. [Google Scholar] [CrossRef]
- Drago, F.; Nozza, P.; Casazza, S.; Brusati, C.; Bandelloni, R.; Rebora, A. Human herpesviruses in bullous pemphigoid lesions. Br. J. Dermatol. 2005, 152, 375–376. [Google Scholar] [CrossRef]
- Sagi, L.; Baum, S.; Agmon-Levin, N.; Sherer, Y.; Katz, B.S.P.; Barzilai, O.; Ram, M.; Bizzaro, N.; Sanmarco, M.; Trau, H.; et al. Autoimmune bullous diseases. The spectrum of infectious agent antibodies and review of the literature. Autoimmun. Rev. 2011, 10, 527–535. [Google Scholar] [CrossRef]
- Barrick, B.; Barrick, J.; Weaver, C.; Lohse, C.; Wieland, C.; Kalaaji, A.; Lehman, J.S. Herpes zoster in patients with bullous pemphigoid: A population-based case-control and cohort study. Br. J. Dermatol. 2016, 174, 1112. [Google Scholar] [CrossRef] [Green Version]
- Blazsek, A.; Silló, P.; Ishii, N.; Jr, P.G.; Poor, G.; Preisz, K.; Hashimoto, T.; Medvecz, M.; Karpati, S. Searching for foreign antigens as possible triggering factors of autoimmunity: Torque Teno virus DNA prevalence is elevated in sera of patients with bullous pemphigoid. Exp. Dermatol. 2008, 17, 446–454. [Google Scholar] [CrossRef]
- Min, M.; Damstetter, E.; Chen, A.Y.-Y. Autoimmune blistering disorders in the setting of human immunodeficiency virus infection. Int. J. Women’s Dermatol. 2018, 4, 159–165. [Google Scholar] [CrossRef]
- De, D.; Kanwar, A.J.; Radotra, B.D.; Narang, T. Bullous eruption in a patient infected with the human immunodeficiency virus. Skinmed 2008, 7, 98–101. [Google Scholar] [CrossRef] [PubMed]
- Bull, R.; Fallowfield, M.; Marsden, R. Autoimmune blistering diseases associated with HIV infection. Clin. Exp. Dermatol. 1994, 19, 47–50. [Google Scholar] [CrossRef] [PubMed]
- Levy, P.; Balavoine, J.; Salomon, D.; Mérot, Y.; Saurat, J. Ritodrine-responsive bullous pemphigoid in a patient with AIDS-related complex. Br. J. Dermatol. 1986, 114, 635–643. [Google Scholar] [CrossRef] [PubMed]
- Jang, H.; Jin, Y.-J.; Yoon, C.H.; Kim, C.-W.; Kim, L. Bullous pemphigoid associated with chronic hepatitis C virus infection in a hepatitis B virus endemic area: A case report. Medicine 2018, 97, e0377. [Google Scholar] [CrossRef] [PubMed]
- Löffel, F.B.; Stücker, M. Localized bullous pemphigoid triggered by erysipelas. Hautarzt 2016, 67, 829–832. [Google Scholar] [CrossRef]
- Bornhövd, E.; Partscht, K.; Flaig, M.J.; Messer, G. Bullous scabies and scabies-triggered bullous pemphigoid. Hautarzt 2001, 52, 56–61. [Google Scholar] [PubMed]
- Mul, V.E.; Van Geest, A.J.; Pijls-Johannesma, M.C.; Theys, J.; Verschueren, T.A.; Jager, J.J.; Lambin, P.; Baumert, B.G. Radiation-induced bullous pemphigoid: A systematic review of an unusual radiation side effect. Radiother. Oncol. 2007, 82, 5–9. [Google Scholar] [CrossRef]
- Dănescu, S.; Chiorean, R.; Macovei, V.; Sitaru, C.; Baican, A. Role of physical factors in the pathogenesis of bullous pemphigoid: Case report series and a comprehensive review of the published work. J. Dermatol. 2015, 43, 134–140. [Google Scholar] [CrossRef]
- Nguyen, T.; Kwan, J.M.; Ahmed, A.R. Relationship between Radiation Therapy and Bullous Pemphigoid. J. Dermatol. 2014, 229, 88–96. [Google Scholar] [CrossRef]
- Hung, T.-L.; Chen, Y.-L.; Lin, K.-T.; Chiang, C.-P.; Chung, C.-H.; Lin, F.-H.; Tsao, C.-H.; Chien, W.-C.; Wang, W.-M.; Hung, C.-T. Risk of radiotherapy-associated autoimmune bullous disease among Taiwanese patients with breast cancer: A case–control study. Arch. Dermatol. Res. 2019, 312, 69–75. [Google Scholar] [CrossRef]
- Tanita, K.; Fujimura, T.; Kambayashi, Y.; Tsukada, A.; Sato, Y.; Hashimoto, A.; Aiba, S. Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab. Case Rep. Oncol. 2018, 11, 114–118. [Google Scholar] [CrossRef] [PubMed]
- Grimaux, X.; Delva, R.; Jadaud, E.; Croue, A. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect. Australas. J. Dermatol. 2018, 60. [Google Scholar] [CrossRef] [PubMed]
- Hirotsu, K.; Chiou, A.S.; Chiang, A.; Kim, J.; Kwong, B.Y.; Pugliese, S. Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy. JAAD Case Rep. 2017, 3, 404–406. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morita, R.; Oiso, N.; Ishii, N.; Tatebayashi, M.; Matsuda, H.; Hashimoto, T.; Kawada, A. Case of burn-associated bullous pemphigoid caused by anti-BP230 immunoglobulin G autoantibodies. J. Dermatol. 2015, 42, 657–658. [Google Scholar] [CrossRef] [PubMed]
- Vassileva, S.; Mateev, G.; Tsankov, N. Burn-Induced Bullous Pemphigoid. Int. J. Dermatol. 1995, 34, 516. [Google Scholar] [CrossRef]
- Bachmeyer, C.; Cabanne-Hamy, A.; Moguelet, P.; Doizi, S.; Callard, P. Bullous Pemphigoid After Boiling Water Burn. South. Med. J. 2010, 103, 1175–1177. [Google Scholar] [CrossRef]
- Chen, D.M.; Fairley, J.A. A bullous pemphigoid-like skin eruption after a chemical burn. J. Am. Acad. Dermatol. 1998, 38, 337–340. [Google Scholar] [CrossRef]
- Massa, M.C.; Freeark, R.J.; Kang, J.S. Localized bullous pemphigoid occurring in a surgical wound. Dermatol. Nurs. 1996, 8, 101–104. [Google Scholar]
- Schiavo, A.L.; Caccavale, S.; Alfano, R.; Gambardella, A.; Cozzi, R. Bullous pemphigoid initially localized around the surgical wound of an arthroprothesis for coxarthrosis. Int. J. Dermatol. 2013, 53. [Google Scholar] [CrossRef]
- McGrath, J.; Black, M. Split skin grafting and bullous pemphigoid. Clin. Exp. Dermatol. 1991, 16, 72–73. [Google Scholar] [CrossRef]
- Ghura, H.S.; Johnston, G.A.; Milligan, A. Development of a bullous pemphigoid after split-skin grafting. Br. J. Plast. Surg. 2001, 54, 447–449. [Google Scholar] [CrossRef] [PubMed]
- Levin, D.L.; Sadhwani, A. Blistering on a squamous cell carcinoma graft site in a patient with bullous pemphigoid. Cutis 1994, 54, 40. [Google Scholar] [PubMed]
- Marzano, A.V.; Vezzoli, P.; Colombo, A.; Serini, S.M.; Crosti, C.; Berti, E. Peristomal bullous pemphigoid. J. Dermatol. 2010, 37, 840–842. [Google Scholar] [CrossRef] [PubMed]
- Batalla, A.; Peón, G.; De la Torre, C. Localized bullous pemphigoid at urostomy site. Indian J. Dermatol. Venereol. Leprol. 2011, 77, 625. [Google Scholar] [CrossRef] [PubMed]
- Valiallah, N.; Ghazavi, M. An asymptomatic bullous eruption arising from an old scar. Br. J. Dermatol. 2015, 173, 14–15. [Google Scholar]
- Caca-Biljanovska, N.; Arsovska-Bezhoska, I.; V’Lckova-Laskoska, M. PUVA-induced Bullous Pemphigoid in Psoriasis. Acta Dermatovenerol. Croat. 2016, 24, 214. [Google Scholar]
- Brun, P.; Baran, R. Bullous pemphigoid induced by PUVA therapy for psoriasis. Report of 2 cases and review of the 6 cases in the literature. Ann. Dermatol. Venereol. 1982, 109, 461–468. [Google Scholar]
- Preesman, A.; Toonstra, J.; Putte, S.; Geer, D.; Weelden, H.; Van Vloten, W. UV-B-induced bullous pemphigoid restricted to mycosis fungoides plaques. Clin. Exp. Dermatol. 1990, 15, 363–366. [Google Scholar] [CrossRef]
- Korekawa, A.; Rokunohe, D.; Akasaka, E.; Fukui, T.; Kitamura, H.; Kaneko, T.; Nakajima, K.; Nakano, H.; Sawamura, D.; Takiyoshi, N.; et al. Mycosis fungoides bullosa associated with bullous pemphigoid. Int. J. Dermatol. 2015, 54, e366–e368. [Google Scholar] [CrossRef]
- Ho, Y.; Hu, H.; Chang, Y.; Li, C.; Wu, C.-Y. Psoriasis is associated with increased risk of bullous pemphigoid: A nationwide population-based cohort study in Taiwan. J. Dermatol. 2019, 46, 604–609. [Google Scholar] [CrossRef]
- Barnadas, M.A.; Gilaberte, M.; Pujol, R.M.; Agustí, M.; Gelpi, C.; AlOmar, A. Bullous pemphigoid in a patient with psoriasis during the course of PUVA therapy: Study by ELISA test. Int. J. Dermatol. 2006, 45, 1089–1092. [Google Scholar] [CrossRef] [PubMed]
- Wilczek, A.; Sticherling, M. Concomitant psoriasis and bullous pemphigoid: Coincidence or pathogenic relationship? Int. J. Dermatol. 2006, 45, 1353–1357. [Google Scholar] [CrossRef] [PubMed]
- Danno, K.; Takigawa, M.; Horio, T. Alterations in Lectin Binding to the Epidermis Following Treatment with 8-Methoxypsoralen Plus Long-Wave Ultraviolet Radiation. J. Investig. Dermatol. 1984, 82, 176–179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- George, P.M. Bullous pemphigoid possibly induced by psoralen plus ultraviolet a therapy. Photodermatol. Photoimmunol. Photomed. 1995, 11, 185–187. [Google Scholar] [CrossRef] [PubMed]
- Caccavale, S.; La Montagna, M. Bullous pemphigoid induced by photodynamic therapy: When light is guilty. Int. J. Dermatol. 2017, 56, e187. [Google Scholar] [CrossRef]
- Rakvit, P.; Kerr, A.C.; Ibbotson, S. Localized bullous pemphigoid induced by photodynamic therapy. Photodermatol. Photoimmunol. Photomed. 2011, 27, 251–253. [Google Scholar] [CrossRef]
- Isohashi, F.; Konishi, K.; Umegaki, N.; Tanei, T.; Koizumi, M.; Yoshioka, Y. A Case of Bullous Pemphigoid Exacerbated by Irradiation after Breast Conservative Radiotherapy. Jpn. J. Clin. Oncol. 2011, 41, 811–813. [Google Scholar] [CrossRef] [Green Version]
- Nieder, C.; Al-Shibli, K.; Tollåli, T. Nontargeted Effect after Radiotherapy in a Patient with Non-Small Cell Lung Cancer and Bullous Pemphigoid. Case Rep. Oncol. Med. 2015, 2015, 1–4. [Google Scholar] [CrossRef] [Green Version]
- Sears, A.; Wee, J.S.; Misch, K.; Natkunarajah, J. Bullous pemphigoid induced by radiotherapy recurring on rechallenge. Clin. Exp. Dermatol. 2012, 37, 916–917. [Google Scholar] [CrossRef]
- Mitsuhashi, Y.; Nakano, H.; Murai, T.; Ohta, T.; Sawamura, D.; Hanada, K.; Hashimoto, I. Bullous Pemphigoid Sera Induce Bullous-Pemphigoid-Like Lesions in Neonatal Mice Pretreated with a Limited Dose of Ultraviolet B Irradiation. Dermatology 1994, 189, 76–81. [Google Scholar] [CrossRef]
- Hall, R.P.; Murray, J.C.; Mccord, M.M.; Rico, M.J.; Streilein, R.D.; Iii, R.P.H. Rabbits Immunized with a Peptide Encoded for by the 230-kD bullous Pemphigoid Antigen cDNA Develop an Enhanced Inflammatory Response to UVB Irradiation: A Potential Animal Model for Bullous Pemphigoid. J. Investig. Dermatol. 1993, 101, 9–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, T.-J.; Lai, P.-C.; Yang, L.-C.; Kuo, T.-T.; Hong, H.-S.; Yang, L.-C. Bullous Pemphigoid in a Renal Transplant Recipient. Am. J. Clin. Dermatol. 2009, 10, 197–200. [Google Scholar] [CrossRef] [PubMed]
- Kerkar, N.; Cohen, S.; Dugan, C.; Morotti, R.A.; Phelps, R.G.; Herold, B.; Shneider, B.; Emre, S. Bullous pemphigoid after liver transplantation for liver failure. Liver Transplant. 2006, 12, 1705–1710. [Google Scholar] [CrossRef]
- Atakan, N.; Tüzün, J.; Karaduman, A. Dyshidrosiform pemphigoid induced by nickel in the diet. Contact Dermat. 1993, 29, 159–160. [Google Scholar] [CrossRef]
- Pomponi, D.; Di Zenzo, G.; Zennaro, D.; Calabresi, V.; Eming, R.; Zuzzi, S.; Bernardi, M.; Scala, E.; Mari, A. Detection of IgG and IgE reactivity to BP180 using the ISAC®microarray system. Br. J. Dermatol. 2013, 168, 1205–1214. [Google Scholar] [CrossRef]
- Büdinger, L.; Borradori, L.; Yee, C.; Eming, R.; Ferencik, S.; Grosse-Wilde, H.; Merk, H.F.; Yancey, K.; Hertl, M. Identification and characterization of autoreactive T-cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J. Clin. Investig. 1998, 102, 2082–2089. [Google Scholar] [CrossRef] [Green Version]
- Okazaki, A.; Miyagawa, S.; Yamashina, Y.; Kitamura, W.; Shirai, T. Polymorphisms of HLA-DR and -DQ genes in Japanese patients with bullous pemphigoid. J. Dermatol. 2000, 27, 149–156. [Google Scholar] [CrossRef]
- Gao, X.-H.; Winsey, S.; Li, G.; Barnardo, M.; Zhu, X.-J.; Chen, H.-D.; Song, F.; Zhai, N.; Fuggle, S.; Wojnarowska, F. HLA-DR and DQ polymorphisms in bullous pemphigoid from northern China. Clin. Exp. Dermatol. 2002, 27, 319–321. [Google Scholar] [CrossRef]
- Esmaili, N.; Mortazavi, H.; Chams-Davatchi, C.; Daneshpazhooh, M.; Damavandi, M.R.; Aryanian, Z.; Amirzargar, A.A. Association between HLA-DQB1*03:01 and Bullous pemphigoid in Iranian patients. Iran. J. Immunol. 2013, 10, 1–9. [Google Scholar]
- Sun, Y.; Liu, H.; Wang, Z.; Fu, X.; Wang, C.; Mi, Z.-H.; Sun, L.; Bao, F.; Yu, G.; Zhou, G.; et al. The HLA-DQB1*03:01 Is Associated with Bullous Pemphigoid in the Han Chinese Population. J. Investig. Dermatol. 2018, 138, 1874–1877. [Google Scholar] [CrossRef] [Green Version]
- Banfield, C.; Wojnarowska, F.; Allen, J.; George, S.; Venning, V.; Welsh, K. The association of HLA-DQ7 with bullous pemphigoid is restricted to men. Br. J. Dermatol. 1998, 138, 1085–1090. [Google Scholar] [CrossRef] [PubMed]
- Chan, L.S.; Hammerberg, C.; Cooper, K.D. Significantly Increased Occurrence of HLA-DQB1∗0301 Allele in Patients with Ocular Cicatricial Pemphigoid. J. Investig. Dermatol. 1997, 108, 129–132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Delgado, J.C.; Turbay, D.; Yunis, E.J.; Morton, E.D.; Bhol, K.; Norman, R.; Alper, C.A.; Good, R.A.; Ahmed, R. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc. Natl. Acad. Sci. USA 1996, 93, 8569–8571. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Setterfield, J.; Theron, J.; Vaughan, R.W.; Welsh, K.; Mallon, E.; Wojnarowska, F.; Challacombe, S.; Black, M. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br. J. Dermatol. 2001, 145, 406–414. [Google Scholar] [CrossRef] [PubMed]
- Ahmed, A.R.; Cohen, E.; Blumenson, L.E.; Provost, T.T. HLA in Bullous Pemphigoid. Arch. Dermatol. 1977, 113, 1121. [Google Scholar] [CrossRef] [PubMed]
- Ahmed, A.R.; Konqui, A.; Park, M.S.; Tiwari, J.L.; Terasaki, P.I. DR Antigens in Bullous Pemphigoid. Arch. Dermatol. 1984, 120, 795. [Google Scholar] [CrossRef]
- Schaller, J.; Feleke, W.; Haustein, U.F.; Baldauf, C.; Kunze, G. HLA in Bullous Pemphigoid: The Probable Role of HLA-B7 as a Marker for Poor Responders to Immunosuppressive Therapy. Int. J. Dermatol. 1991, 30, 36–38. [Google Scholar] [CrossRef]
- Venning, V.; Taylor, C.; Ting, A.; Wojnarowska, F. HLA type in bullous pemphigoid, cicatricial pemphigoid and linear IgA disease. Clin. Exp. Dermatol. 1989, 14, 283–285. [Google Scholar] [CrossRef]
- Brochado, M.J.F.; Nascimento, D.F.; Campos, W.; Deghaide, N.H.S.; Donadi, E.; Roselino, A.M. Differential HLA class I and class II associations in pemphigus foliaceus and pemphigus vulgaris patients from a prevalent Southeastern Brazilian region. J. Autoimmun. 2016, 72, 19–24. [Google Scholar] [CrossRef]
- Fang, H.; Shen, S.; Zheng, X.; Dang, E.; Zhang, J.; Shamsaei, N.; Qiao, P.; Li, Q.; Wang, H.; Li, C.; et al. Association of HLA class I and class II alleles with bullous pemphigoid in Chinese Hans. J. Dermatol. Sci. 2017, 89, 258–262. [Google Scholar] [CrossRef] [Green Version]
- Hirose, M.; Schilf, P.; Benoit, S.; Eming, R.; Gläser, R.; Homey, B.; Kunz, M.; Nebel, A.; Peitsch, W.K.; Pföhler, C.; et al. Polymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German population. Exp. Dermatol. 2015, 24, 715–717. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jedlickova, H.; Hlubinka, M.; Pavlik, T.; Semradova, V.; Budinská, E.; Vlasin, Z. Bullous pemphigoid and internal diseases—A case-control study. Eur. J. Dermatol. 2010, 20, 96–101. [Google Scholar] [CrossRef] [PubMed]
- Taghipour, K.; Chi, C.; Vincent, A.; Groves, R.W.; Venning, V.; Wojnarowska, F. The Association of Bullous Pemphigoid with Cerebrovascular Disease and Dementia. Arch. Dermatol. 2010, 146, 1251–1254. [Google Scholar] [CrossRef] [Green Version]
- Langan, S.M.; Groves, R.W.; West, J. The Relationship between Neurological Disease and Bullous Pemphigoid: A Population-Based Case–Control Study. J. Investig. Dermatol. 2011, 131, 631–636. [Google Scholar] [CrossRef] [Green Version]
- Jeon, H.W.; Yun, S.J.; Lee, S.-C.; Won, Y.H.; Lee, J.-B. Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea. Ann. Dermatol. 2018, 30. [Google Scholar] [CrossRef] [Green Version]
- Chen, Y.; Wu, C.; Lin, M.J.; Chen, T.; Liao, K.; Hwang, C.; Chu, S.; Chen, C.; Lee, D.; Chang, Y.-T.; et al. Comorbidity profiles among patients with bullous pemphigoid: A nationwide population-based study. Br. J. Dermatol. 2011, 165, 593–599. [Google Scholar] [CrossRef] [PubMed]
- Oh, D.; Zhao, C.; Murrell, D. A review of case-control studies on the risk factors for the development of autoimmune blistering diseases. J. Eur. Acad. Dermatol. Venereol. 2015, 30, 595–603. [Google Scholar] [CrossRef] [PubMed]
- Kibsgaard, L.; Rasmussen, M.; Lamberg, A.; Deleuran, M.; Olesen, A.; Vestergaard, C. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: A population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br. J. Dermatol. 2017, 176, 1486–1491. [Google Scholar] [CrossRef] [PubMed]
- Lai, Y.; Yew, Y.; Lambert, W. Bullous pemphigoid and its association with neurological diseases: A systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol. 2016, 30, 2007–2015. [Google Scholar] [CrossRef]
- Laffitte, E.; Burkhard, P.; Fontao, L.; Jaunin, F.; Saurat, J.-H.; Chofflon, M.; Borradori, L. Bullous pemphigoid antigen 1 isoforms: Potential new target autoantigens in multiple sclerosis? Br. J. Dermatol. 2005, 152, 537–540. [Google Scholar] [CrossRef]
- Foureur, N.; Mignot, S.; Senet, P.; Verpillat, P.; Picard-Dahan, C.; Crickx, B.; Labarre, C.; Nicaise-Roland, P.; Descamps, V. Correlation between the presence of type-2 anti-pemphigoid antibodies and dementia in elderly subjects with no clinical signs of pemphigoid. Ann. Dermatol. Venereol. 2006, 133, 439–443. [Google Scholar] [CrossRef]
- Kokkonen, N.; Herukka, S.-K.; Huilaja, L.; Kokki, M.; Koivisto, A.M.; Hartikainen, P.; Remes, A.M.; Tasanen, K. Increased Levels of the Bullous Pemphigoid BP180 Autoantibody Are Associated with More Severe Dementia in Alzheimer’s Disease. J. Investig. Dermatol. 2017, 137, 71–76. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taghipour, K.; Chi, C.; Bhogal, B.; Groves, R.; Venning, V.; Wojnarowska, F. Immunopathological characteristics of patients with bullous pemphigoid and neurological disease. J. Eur. Acad. Dermatol. Venereol. 2013, 28, 569–573. [Google Scholar] [CrossRef] [PubMed]
- Gornowicz-Porowska, J.; Seraszek-Jaros, A.; Bowszyc-Dmochowska, M.; Kaczmarek, E.; Pietkiewicz, P.; Bartkiewicz, P.; Dmochowski, M. Analysis of the autoimmune response against BP180 and BP230 in ethnic Poles with neurodegenerative disorders and bullous pemphigoid. Central Eur. J. Immunol. 2017, 42, 85–90. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seppänen, A.; Autio-Harmainen, H.; Alafuzoff, I.; Särkioja, T.; Veijola, J.; Hurskainen, T.; Bruckner-Tuderman, L.; Tasanen, K.; Majamaa, K. Collagen XVII is expressed in human CNS neurons. Matrix Biol. 2006, 25, 185–188. [Google Scholar] [CrossRef] [PubMed]
- Teixeira, V.; Cabral, R.; Brites, M.M.; Vieira, R.; Figueiredo, A. Bullous pemphigoid and comorbidities: A case-control study in Portuguese patients*. An. Bras. Dermatol. 2014, 89, 274–279. [Google Scholar] [CrossRef] [PubMed]
- Brick, K.E.; Weaver, C.H.; Savica, R.; Lohse, C.M.; Pittelkow, M.R.; Boeve, B.F.; Gibson, L.E.; Camilleri, M.J.; Wieland, C.N. A population-based study of the association between bullous pemphigoid and neurologic disorders. J. Am. Acad. Dermatol. 2014, 71, 1191–1197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cai, S.; Allen, J.; Lim, Y.; Chua, S.; Tan, S.; Tang, M. Mortality of bullous pemphigoid in Singapore: Risk factors and causes of death in 359 patients seen at the National Skin Centre. Br. J. Dermatol. 2014, 170, 1319–1326. [Google Scholar] [CrossRef]
- Lillicrap, D.A.; Bett, D.G. Rheumatoid Arthritis and Pemphigoid. Proc. R. Soc. Med. 1963, 56, 921–922. [Google Scholar] [CrossRef] [Green Version]
- Callen, J.P. Internal disorders associated with bullous disease of the skin. J. Am. Acad. Dermatol. 1980, 3, 107–119. [Google Scholar] [CrossRef]
- Taylor, G.; Venning, V.; Wojnarowska, F.; Welch, K. Bullous pemphigoid and autoimmunity. J. Am. Acad. Dermatol. 1993, 29, 181–184. [Google Scholar] [CrossRef]
- Callen, J.P.; Anderson, T.F.; Chanda, J.J.; Taylor, W.B. Bullous pemphigoid and other disorders associated with autoimmune phenomena. Arch. Dermatol. 1978, 114, 245–246. [Google Scholar] [CrossRef]
- Giannini, J.M.; Callen, J.P.; Gruber, G.G. Bullous pemphigoid and rheumatoid arthritis. J. Am. Acad. Dermatol. 1981, 4, 695–697. [Google Scholar] [CrossRef]
- Savin, J.A. The events leading to the death of patients with pemphigus and pemphigoid. Br. J. Dermatol. 1979, 101, 521–534. [Google Scholar] [CrossRef] [PubMed]
- Dahl, M.V. Bullous pemphigoid: Associated diseases. Clin. Dermatol. 1987, 5, 64–70. [Google Scholar] [CrossRef]
- Person, J.R.; Rogers, R.S. Benign: Bullous and cicatricial pemphigoid, clinical, histopathologic and immunopathologic correlations. Plast. Reconstr. Surg. 1977, 60, 486. [Google Scholar] [CrossRef]
- Dainichi, T.; Kabashima, K. Interaction of Psoriasis and Bullous Diseases. Front. Med. 2018, 5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tsai, T.F.; Wang, T.-S.; Hung, S.-T.; Tsai, P.I.-C.; Schenkel, B.; Zhang, M.; Tang, C.-H. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J. Dermatol. Sci. 2011, 63, 40–46. [Google Scholar] [CrossRef]
- Kridin, K.; Zelber-Sagi, S.; Comaneshter, R.; Cohen, A.D. Association between pemphigus and psoriasis: A population-based large-scale study. J. Am. Acad. Dermatol. 2017, 77, 1174–1175. [Google Scholar] [CrossRef] [PubMed]
- Ohata, C.; Ishii, N.; Koga, H.; Fukuda, S.; Tateishi, C.; Tsuruta, D.; Furumura, M.; Hashimoto, T. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases. J. Am. Acad. Dermatol. 2015, 73, 50–55. [Google Scholar] [CrossRef]
- Balestri, R.; Magnano, M.; La Placa, M.; Patrizi, A.; Angileri, L.; Tengattini, V.; Bardazzi, F. Malignancies in bullous pemphigoid: A controversial association. J. Dermatol. 2015, 43, 125–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Atzmony, L.; Mimouni, I.; Reiter, O.; Leshem, Y.A.; Taha, O.; Gdalevich, M.; Hodak, E.; Mimouni, D. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2017, 77, 691–699. [Google Scholar] [CrossRef] [PubMed]
- Lucariello, R.J.; E Villablanca, S.; Mascaró, J.; Reichel, M. Association between bullous pemphigoid and malignancy: A meta-analysis. Australas. J. Dermatol. 2018, 59, 253–260. [Google Scholar] [CrossRef]
- Schulze, F.; Neumann, K.; Recke, A.; Zillikens, D.; Linder, R.; Schmidt, E. Malignancies in Pemphigus and Pemphigoid Diseases. J. Investig. Dermatol. 2015, 135, 1445–1447. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ong, E.; Goldacre, R.; Hoang, U.; Sinclair, R.; Goldacre, M. Associations between bullous pemphigoid and primary malignant cancers: An English national record linkage study, 1999–2011. Arch. Dermatol. Res. 2013, 306, 75–80. [Google Scholar] [CrossRef]
- Bech, R.; Kibsgaard, L.; Vestergaard, C. Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature. Front. Med. 2018, 5. [Google Scholar] [CrossRef]
- Yan, T.M.; Zuo, Y.G. Coagulation Disorders in Bullous Pemphigoid and Its Mechanism. Acta Acad. Med. Sin. 2019, 41, 685–689. [Google Scholar]
- Roujeau, J.-C.; Lok, C.; Bastuji-Garin, S.; Mhalla, S.; Enginger, V.; Bernard, P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch. Dermatol. 1998, 134, 465–469. [Google Scholar] [CrossRef]
- Echigo, T.; Hasegawa, M.; Inaoki, M.; Yamazaki, M.; Sato, S.; Takehara, K. Antiphospholipid antibodies in patients with autoimmune blistering disease. J. Am. Acad. Dermatol. 2007, 57, 397–400. [Google Scholar] [CrossRef] [Green Version]
- Langan, S.M.; Hubbard, R.; Fleming, K.M.; West, J. A population-based study of acute medical conditions associated with bullous pemphigoid. Br. J. Dermatol. 2009, 161, 1149–1152. [Google Scholar] [CrossRef]
- Yang, Y.-W.; Chen, Y.-H.; Xirasagar, S.; Lin, H.-C. Increased Risk of Stroke in Patients With Bullous Pemphigoid. Stroke 2011, 42, 319–323. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marzano, A.V.; Tedeschi, A.; Polloni, I.; Crosti, C.; Cugno, M. Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. Clin. Exp. Immunol. 2012, 171, 76–81. [Google Scholar] [CrossRef] [PubMed]
- Miyakis, S.; Lockshin, M.D.; Atsumi, T.; Branch, D.W.; Brey, R.L.; Cervera, R.; Derksen, R.H.W.M.; De Groot, P.G.; Koike, T.; Meroni, P.L.; et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 4, 295–306. [Google Scholar] [CrossRef] [PubMed]
- De Amorim, L.C.D.; Maia, F.M.; Rodrigues, C.E.M. Stroke in systemic lupus erythematosus and antiphospholipid syndrome: Risk factors, clinical manifestations, neuroimaging, and treatment. Lupus 2017, 26, 529–536. [Google Scholar] [CrossRef] [PubMed]
- Gin, H.; Vergnot, V.; Diakou, V.; Perret, A.-M.; Poix, J.; Cassagne, C.; Maneta-Peyret, L. Anti-Phospholipid Antibodies in Diabetes Mellitus. Clin. Chem. Lab. Med. 2002, 40. [Google Scholar] [CrossRef]
- Abaci, A.; Bober, E.; Yesikaya, E.; Bidec, A.; Cinaz, P.; Buyukgebiz, A. Prevalence of anticardiolipin antibodies in type 1 diabetes and autoimmune thyroiditis. Pol. Arch. Med. Wewn. 2010, 120, 71–75. [Google Scholar] [CrossRef]
- Kaji, M.; Sato, Y.; Kunoh, H.; Watanabe, A.; Aizawa, H.; Oizumi, K.; Abe, T. Antiphospholipid Syndrome and Multiple Ischemic Strokes in a Patient with Myasthenia Gravis. Kurume Med. J. 2002, 49, 211–216. [Google Scholar] [CrossRef] [Green Version]
- Versini, M. Thyroid Autoimmunity and Antiphospholipid Syndrome: Not Such a Trivial Association. Front. Endocrinol. 2017, 8. [Google Scholar] [CrossRef] [Green Version]
- Koutroubakis, I.E.; Petinaki, E.; Anagnostopoulou, E.; Kritikos, H.; Mouzas, I.A.; Kouroumalis, E.A.; Manousos, O.N. Anti-cardiolipin and Anti-β2-glycoprotein I Antibodies in Patients with Inflammatory Bowel Disease. Dig. Dis. Sci. 1998, 43, 2507–2512. [Google Scholar] [CrossRef]
- Mouelhi, L.; Mekki, H.; Debbeche, R.; Salem, M.; Najjar, T. Thromboses au cours des maladies inflammatoires chroniques de l’intestin: Mecanismes et facteurs de risqué. Tunis. Med. 2009, 87, 307–310. [Google Scholar]
- Roubey, R.A.S. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum. 1996, 39, 1444–1454. [Google Scholar] [CrossRef] [PubMed]
- Riboldi, P. Endothelium as a target for antiphospholipid antibodies. Immunobiology 2003, 207, 29–36. [Google Scholar] [CrossRef] [PubMed]
- Bucciarelli, P.; Balice, Y.; Cianchini, G.; Quaglino, P.; Calzavara-Pinton, P.; Caproni, M.; Alaibac, M.; De Simone, C.; Patrizi, A.; Cozzani, E.; et al. Increased risk of venous thromboembolism in patients with bullous pemphigoid. Thromb. Haemost. 2016, 115, 193–199. [Google Scholar] [CrossRef] [PubMed]
- Joly, P.; Bénichou, J.; Lok, C.; Hellot, M.F.; Saiag, P.; Tancrède-Bohin, E.; Sassolas, B.; Labeille, B.; Doutre, M.S.; Gorin, I.; et al. Prediction of Survival for Patients With Bullous Pemphigoid. Arch. Dermatol. 2005, 141, 691–698. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ungprasert, P.; Wijarnpreecha, K.; Thongprayoon, C. Risk of venous thromboembolism in patients with bullous pemphigoid: A systematic review and meta-analysis. Indian J. Dermatol. Venereol. Leprol. 2017, 84, 22–26. [Google Scholar] [CrossRef]
- Cugno, M.; Borghi, A.; Garcovich, S.; Marzano, A.V. Coagulation and Skin Autoimmunity. Front. Immunol. 2019, 10. [Google Scholar] [CrossRef]
- Giusti, D.; Gatouillat, G.; Le Jan, S.; Plée, J.; Bernard, P.; Antonicelli, F.; Pham, B.N. Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome. Sci. Rep. 2017, 7, 4833. [Google Scholar] [CrossRef] [Green Version]
- Tedeschi, A.; Marzano, A.; Lorini, M.; Balice, Y.; Cugno, M. Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid. J. Eur. Acad. Dermatol. Venereol. 2014, 29, 813–817. [Google Scholar] [CrossRef]
- Wakugawa, M.; Nakamura, K.; Hino, H.; Toyama, K.; Hattori, N.; Okochi, H.; Yamada, H.; Hirai, K.; Tamaki, K.; Furue, M. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: Correlation with tissue eosinophilia. Br. J. Dermatol. 2000, 143, 112–116. [Google Scholar] [CrossRef]
- Engineer, L.; Bhol, K.; Kumari, S.; Ahmed, A.R. Bullous pemphigoid: Interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation. Cytokine 2001, 13, 32–38. [Google Scholar] [CrossRef]
- Frezzolini, A.; Cianchini, G.; Ruffelli, M.; Cadoni, S.; Puddu, P.; De Pità, O. Interleukin-16 expression and release in bullous pemphigoid. Clin. Exp. Immunol. 2004, 137, 595–600. [Google Scholar] [CrossRef] [PubMed]
- Amber, K.T.; Valdebran, M.; Kridin, K.; Grando, S.A. The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease. Front. Med. 2018, 5. [Google Scholar] [CrossRef] [PubMed]
- Shimanovich, I.; Mihai, S.; Oostingh, G.J.; Ilenchuk, T.T.; Bröcker, E.-B.; Opdenakker, G.; Zillikens, D.; Sitaru, C. Granulocyte-derived elastase and gelatinase B are required for dermal–epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J. Pathol. 2004, 204, 519–527. [Google Scholar] [CrossRef] [PubMed]
- Ståhle-Bäckdahl, M.; Inoue, M.; Guidice, G.J.; Parks, W.C. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J. Clin. Investig. 1994, 93, 2022–2030. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marzano, A.; Tedeschi, A.; Fanoni, D.; Bonanni, E.; Venegoni, L.; Berti, E.; Cugno, M. Activation of blood coagulation in bullous pemphigoid: Role of eosinophils, and local and systemic implications. Br. J. Dermatol. 2009, 160, 266–272. [Google Scholar] [CrossRef] [PubMed]
- Marzano, A.V.; Tedeschi, A.; Berti, E.; Fanoni, D.; Crosti, C.; Cugno, M. Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases. Clin. Exp. Immunol. 2011, 165, 44–50. [Google Scholar] [CrossRef]
- DeMichele, M.A.; Moon, D.G.; Fenton, J.W.; Minnear, F.L. Thrombin’s enzymatic activity increases permeability of endothelial cell monolayers. J. Appl. Physiol. 1990, 69, 1599–1606. [Google Scholar] [CrossRef] [PubMed]
- Marzano, A.V.; Tedeschi, A.; Spinelli, D.; Fanoni, D.; Crosti, C.; Cugno, M. Coagulation activation in autoimmune bullous diseases. Clin. Exp. Immunol. 2009, 158, 31–36. [Google Scholar] [CrossRef]
- Cugno, M.; Tedeschi, A.; Borghi, A.; Bucciarelli, P.; Asero, R.; Venegoni, L.; Griffini, S.; Grovetti, E.; Berti, E.; Marzano, A.V. Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk. PLoS ONE 2015, 10, e0129456. [Google Scholar] [CrossRef] [Green Version]
- Watad, A.; Bragazzi, N.L.; Adawi, M.; Amital, H.; Toubi, E.; Porat, B.-S.; Shoenfeld, Y. Autoimmunity in the Elderly: Insights from Basic Science and Clinics—A Mini-Review. Gerontology 2017, 63, 515–523. [Google Scholar] [CrossRef] [Green Version]
- Mehr, R.; Melamed, D. Reversing B cell aging. Aging 2011, 3, 438–443. [Google Scholar] [CrossRef] [PubMed]
- Szabo, P.; Shen, S.; Telford, W.; Weksler, M.E. Impaired rearrangement of IgH V to DJ segments in bone marrow Pro-B cells from old mice. Cell. Immunol. 2003, 222, 78–87. [Google Scholar] [CrossRef]
- Duggal, N.A.; Upton, J.; Phillips, A.C.; Sapey, E.; Lord, J. An age-related numerical and functional deficit in CD19+CD24hiCD38hi B cells is associated with an increase in systemic autoimmunity. Aging Cell 2013, 12, 873–881. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weiskopf, D.; Weinberger, B.; Grubeck-Loebenstein, B. The aging of the immune system. Transpl. Int. 2009, 22, 1041–1050. [Google Scholar] [CrossRef] [PubMed]
- Naradikian, M.S.; Hao, Y.; Cancro, M.P. Age-associated B cells: Key mediators of both protective and autoreactive humoral responses. Immunol. Rev. 2015, 269, 118–129. [Google Scholar] [CrossRef]
- Vadasz, Z.; Haj, T.; Kessel, A.; Toubi, E. Age-related autoimmunity. BMC Med. 2013, 11, 94. [Google Scholar] [CrossRef]
- Akha, A.A.S. Aging and the immune system: An overview. J. Immunol. Methods 2018, 463, 21–26. [Google Scholar] [CrossRef]
- Karnell, J.L.; Kumar, V.; Wang, J.; Wang, S.; Voynova, E.; Ettinger, R. Role of CD11c+ T-bet+ B cells in human health and disease. Cell. Immunol. 2017, 321, 40–45. [Google Scholar] [CrossRef]
- Rubtsov, A.V.; Rubtsova, K.; Fischer, A.; Meehan, R.T.; Gillis, J.Z.; Kappler, J.W.; Marrack, P. Toll-like receptor 7 (TLR7)–driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity. Blood 2011, 118, 1305–1315. [Google Scholar] [CrossRef] [Green Version]
- Lindstrom, T.M.; Robinson, W.H. Rheumatoid arthritis: A role for immunosenescence? J. Am. Geriatr. Soc. 2010, 58, 1565–1575. [Google Scholar] [CrossRef] [Green Version]
- Pereira, B.I.; Akbar, A.N. Convergence of Innate and Adaptive Immunity during Human Aging. Front. Immunol. 2016, 7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ponnappan, S.; Ponnappan, U. Aging and Immune Function: Molecular Mechanisms to Interventions. Antioxid. Redox Signal. 2011, 14, 1551–1585. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mellanby, R.J.; Thomas, D.C.; Lamb, J. Role of regulatory T-cells in autoimmunity. Clin. Sci. 2009, 116, 639–649. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Linehan, E.; Fitzgerald, D.C. Ageing and the immune system: Focus on macrophages. Eur. J. Microbiol. Immunol. 2015, 5, 14–24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fortin, C.; McDonald, P.P.; Lesur, O.; Fülöp, T. Aging and Neutrophils: There Is Still Much to Do. Rejuvenation Res. 2008, 11, 873–882. [Google Scholar] [CrossRef] [PubMed]
- Grolleau-Julius, A.; Ray, D.; Yung, R. The Role of Epigenetics in Aging and Autoimmunity. Clin. Rev. Allergy Immunol. 2009, 39, 42–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Immune Checkpoint Inhibitors Targeting Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death-Ligand 1 (PD-L1) | Antibiotics | Calcium Channel Blockers | Angiotensin-Converting-Enzyme Inhibitors (ACE Inhibitors) | β-Blockers | NSAID | Salicylates | Dipeptidyl Peptidase 4 Inhibitors | Diuretics | Others Antidiabetics | Anti TNF-α | Others |
---|---|---|---|---|---|---|---|---|---|---|---|
Pembrolizumab | Actinomycin | Amlodipine | CapTopril | Atenolol | Azapropazone | Aspirin | Sitagliptin | Furosemide | Tolbutamide | Adalimumab | Arsenic |
Nivolumab | Amoxicillin | Nifedipine | Enalapril | Nadolol | Colecoxib | Sulphasalazine | Vildagliptin | Spironolactone | Efalizumab | Doxepin | |
Durvalumab | Ampicillin | Lisinopril | Practolol | Diclofenac (topical) | Salicylazosulphapyride | Alogliptin | Bumetanide | Etanercept | Clonidine | ||
Cephalexin | Angiotens. II antagonists | Ibuprofen | Linagliptin | Infliximab | Erlotinib | ||||||
Ciprofloxacin | Losartan | Mefenamic acid | TeneLIgliptin | Escitalopram | |||||||
Chloroquine | Phenacetin | Saxagliptin | Everolimus | ||||||||
Dactinomycin | Anagliptin | Fluoxetine | |||||||||
Griseofulvin | Flupenthixol | ||||||||||
Levofloxacin | Gabapentine | ||||||||||
Metronidazol | Galantamine hydrobromide | ||||||||||
Penicilline | Gold thiosulphate | ||||||||||
Rifampicin | Interleukin-2 | ||||||||||
Iodinate contrast (IV iodine + etanercept) | |||||||||||
Levetiracetam | |||||||||||
Methyldopa | |||||||||||
Methotrexate | |||||||||||
Terbinafine | |||||||||||
Thiopronin | |||||||||||
Omeprazole | |||||||||||
Psoralens with UVA | |||||||||||
Placental extracts | |||||||||||
Potassium iodide | |||||||||||
Risperidone | |||||||||||
Rosuvastatin | |||||||||||
Sulphonamide | |||||||||||
Ustekinumab |
Neurologic Diseases | Autoimmune Diseases | Neoplasms | Cardiovascular Diseases |
---|---|---|---|
Stroke | Psoriasis | Kidney cancer | Thromboembolism |
Dementia | Rheumatoid arthritis | Laryngeal cancer | Stroke |
Parkinson’s disease | Lupus erythematosus | Hematologic malignancies | Venous thromboembolism |
Alzheimer’s disease | Lichen planus | Pulmonary embolism | |
Multiple sclerosis | Membranous nephropathy | ||
Epilepsy | Pernicious anemia | ||
Schizophrenia | Primary biliary cirrhosis | ||
Thyroiditis | |||
Multiple sclerosis | |||
Polymyositis |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Moro, F.; Fania, L.; Sinagra, J.L.M.; Salemme, A.; Di Zenzo, G. Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules 2020, 10, 1432. https://doi.org/10.3390/biom10101432
Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules. 2020; 10(10):1432. https://doi.org/10.3390/biom10101432
Chicago/Turabian StyleMoro, Francesco, Luca Fania, Jo Linda Maria Sinagra, Adele Salemme, and Giovanni Di Zenzo. 2020. "Bullous Pemphigoid: Trigger and Predisposing Factors" Biomolecules 10, no. 10: 1432. https://doi.org/10.3390/biom10101432
APA StyleMoro, F., Fania, L., Sinagra, J. L. M., Salemme, A., & Di Zenzo, G. (2020). Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules, 10(10), 1432. https://doi.org/10.3390/biom10101432